Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2014
Exchange: NASDAQ
Website: sagerx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/21/2024 | $4.00 | Underperform → Sector Perform | RBC Capital Mkts |
| 10/10/2024 | Mkt Perform | Raymond James | |
| 10/4/2024 | $10.00 → $4.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 7/30/2024 | $16.00 → $10.00 | Buy → Hold | TD Cowen |
| 7/25/2024 | $18.00 → $12.00 | Overweight → Neutral | JP Morgan |
| 5/29/2024 | $15.00 | Neutral | Robert W. Baird |
| 5/29/2024 | $8.00 | Sell | Citigroup |
| 4/17/2024 | $24.00 → $14.00 | Neutral → Underperform | BofA Securities |
| 12/12/2023 | $21.00 | Hold | Deutsche Bank |
| 8/8/2023 | $22.00 | Buy → Neutral | Goldman |
8-K - Sage Therapeutics, Inc. (0001597553) (Filer)
8-K - Sage Therapeutics, Inc. (0001597553) (Filer)
10-Q - Sage Therapeutics, Inc. (0001597553) (Filer)
8-K - Sage Therapeutics, Inc. (0001597553) (Filer)
8-K - Sage Therapeutics, Inc. (0001597553) (Filer)
8-K - Sage Therapeutics, Inc. (0001597553) (Filer)
8-K - Sage Therapeutics, Inc. (0001597553) (Filer)
S-3ASR - Sage Therapeutics, Inc. (0001597553) (Filer)
10-Q - Sage Therapeutics, Inc. (0001597553) (Filer)
8-K - Sage Therapeutics, Inc. (0001597553) (Filer)
For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas
For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health
4 - Sage Therapeutics, Inc. (0001597553) (Issuer)
4 - Sage Therapeutics, Inc. (0001597553) (Issuer)
3 - Sage Therapeutics, Inc. (0001597553) (Issuer)
4 - Sage Therapeutics, Inc. (0001597553) (Issuer)
4 - Sage Therapeutics, Inc. (0001597553) (Issuer)
4 - Sage Therapeutics, Inc. (0001597553) (Issuer)
4 - Sage Therapeutics, Inc. (0001597553) (Issuer)
4 - Sage Therapeutics, Inc. (0001597553) (Issuer)
4 - Sage Therapeutics, Inc. (0001597553) (Issuer)
4 - Sage Therapeutics, Inc. (0001597553) (Issuer)
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230316005117/en/Jessica Federer (Photo: Business Wire) "We are thrilled to have Jessica join our Board of Directors. Jessica is a champion for patients and has a track record of innovation in data and digital transformation which will be a key future growth driver for the industry," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Jessica's innate curiosit
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Laura Gault, MD, Ph.D. as Chief Medical Officer. In her new role, Dr. Gault will focus on advancing Sage's current and emerging product pipeline through all stages of development. "We are thrilled to have Dr. Gault join Sage to lead the development and delivery of our pipeline of potential new medicines and be a partner in our mission to improve the lives of people affected by brain health disorders," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Dr. Gault's vision, experience and deep commitment to this field of med
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the appointment of Chris Benecchi as Chief Commercial Officer. In his new role, Mr. Benecchi will lead Sage's global commercial efforts across all Sage programs, new product planning, strategy, and competitive intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005386/en/Chris Benecchi, Chief Commercial Officer, Sage Therapeutics (Photo: Business Wire) "Chris Benecchi is an innovator, a transformative global
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that, as part of the Company’s plan to accelerate growth and leverage the talents of the leaders in the brain health space, Barry Greene has been appointed chief executive officer. Mr. Greene, who most recently served as president of Alnylam Pharmaceuticals, Inc., from 2007 to September 2020, and as its chief operating officer from 2003 to 2016, will also continue as a member of Sage’s board of directors. “Sage is taking on one of the biggest cha
SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)
SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)
SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)
SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)
SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)
SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)
SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)
SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)
SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)
SC 13G - Sage Therapeutics, Inc. (0001597553) (Subject)
The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data, the Company does not plan further development of dalzanemdor Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington's Disease (HD). In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test (SDMT) at Day 84. Analyses of secondary endpoints did not demonstr
Achieved $11 million in ZURZUVAE® (zuranolone) collaboration revenue during the third quarter of 2024 (50% of the net revenue recorded by Biogen), representing 49% growth from the second quarter Sage and Biogen will not pursue further development of zuranolone in major depressive disorder (MDD) in the U.S. Topline data from the DIMENSION Study in Huntington's Disease (HD) expected late 2024 Cash, cash equivalents and marketable securities of $569 million as of September 30, 2024 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the third quarter ended September 30, 2024. "We are committed to harnessing the full potential of ZURZUVAE as
Planned workforce reduction of approximately 33% of employees expected to extend the company's cash runway Sage Therapeutics, Inc. (NASDAQ:SAGE), today announced a strategic reorganization of its business operations to support the ongoing launch of ZURZUVAE in postpartum depression and focus pipeline development efforts ahead of a clinical study readout for dalzanemdor in Huntington's Disease expected later this year. The reorganization is intended to enable Sage to strengthen its balance sheet, extend cash runway, and position the company for long-term growth potential. The reorganization is planned to be substantially completed by the end of the 4th quarter of 2024 and expected to: Im
Sage Therapeutics, Inc. (NASDAQ:SAGE), today announced that it will host a live webcast on Tuesday, October 29, 2024 at 4:30 p.m. ET to review third quarter 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments ind
Approximately one in eight U.S. women report experiencing postpartum depression symptoms1 yet care pathways remain complex, leading to delayed diagnosis and treatmentTalkiatry to offer new resources and expand access to care for women experiencing postpartum mental health challenges by virtually connecting them with a provider from the comfort of their own homeNEW YORK, Oct. 8, 2024 /PRNewswire/ -- Talkiatry, a leading provider of high-quality, in-network psychiatric care, today announced a new pathway for postpartum mental health support that can help improve access to care for women in need. Through the launch of Talkiatry's new educational resources, women can learn about the signs and sy
- In the Phase 2 LIGHTWAVE Study, dalzanemdor (SAGE-718) did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the primary endpoint - Dalzanemdor was generally well-tolerated and no new safety signals were observed - Topline data from the Phase 2 DIMENSION Study of dalzanemdor in Huntington's Disease expected later this year Sage Therapeutics, Inc. (NASDAQ:SAGE) announced today topline results from LIGHTWAVE, a 12-week, Phase 2 randomized, double-blind, placebo-controlled study to evaluate the effects of dalzanemdor (SAGE-718) in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheime
Sage and Biogen will continue to partner on ZURZUVAE®, the first and only FDA-approved oral treatment for women with postpartum depression Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Biogen has terminated its rights under the collaboration and license agreement with Sage specific to the SAGE-324 program. The companies recently announced negative results from the Phase 2 KINETIC 2 Study of investigational SAGE-324 for the chronic treatment of essential tremor (ET) and discontinued further clinical development of SAGE-324 in ET. Sage and Biogen will continue to partner on ZURZUVAE® (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depressi
Achieved $7.4 million in ZURZUVAE™ (zuranolone) collaboration revenue during the second quarter of 2024 (50% of the net revenues recorded by Biogen), representing 19% growth from the first quarter More than 1,400 prescriptions shipped and delivered during the second quarter of 2024, nearly doubling from the first quarter Dalzanemdor (SAGE-718) topline data from the LIGHTWAVE (Alzheimer's Disease) and DIMENSION (Huntington's Disease) Studies expected in late 2024; primary endpoint for DIMENSION Study adjusted from HD-CAB composite to the Symbol Digit Modalities Test (SDMT) SAGE-324 did not meet the primary endpoint in participants with essential tremor (ET); Sage and Biogen terminated
- SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor - No statistically significant differences were demonstrated between any dose of SAGE-324 and placebo in the change from baseline for the primary endpoint Sage Therapeutics, Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 (BIIB124) as a potential treatment in essential tremor (ET). The KINETIC 2 Study did not demonstrate a statistically significant dose-response relationship in change from baseline to Day 91 based on the
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, July 31, 2024 at 4:30 p.m. ET to review second quarter 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health med
RBC Capital Mkts upgraded SAGE Therapeutics from Underperform to Sector Perform and set a new price target of $4.00
Raymond James resumed coverage of SAGE Therapeutics with a rating of Mkt Perform
RBC Capital Mkts downgraded SAGE Therapeutics from Outperform to Sector Perform and set a new price target of $4.00 from $10.00 previously
TD Cowen downgraded SAGE Therapeutics from Buy to Hold and set a new price target of $10.00 from $16.00 previously
JP Morgan downgraded SAGE Therapeutics from Overweight to Neutral and set a new price target of $12.00 from $18.00 previously
Robert W. Baird initiated coverage of SAGE Therapeutics with a rating of Neutral and set a new price target of $15.00
Citigroup initiated coverage of SAGE Therapeutics with a rating of Sell and set a new price target of $8.00
BofA Securities downgraded SAGE Therapeutics from Neutral to Underperform and set a new price target of $14.00 from $24.00 previously
Deutsche Bank initiated coverage of SAGE Therapeutics with a rating of Hold and set a new price target of $21.00
Goldman downgraded SAGE Therapeutics from Buy to Neutral and set a new price target of $22.00
Achieved $11 million in ZURZUVAE® (zuranolone) collaboration revenue during the third quarter of 2024 (50% of the net revenue recorded by Biogen), representing 49% growth from the second quarter Sage and Biogen will not pursue further development of zuranolone in major depressive disorder (MDD) in the U.S. Topline data from the DIMENSION Study in Huntington's Disease (HD) expected late 2024 Cash, cash equivalents and marketable securities of $569 million as of September 30, 2024 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the third quarter ended September 30, 2024. "We are committed to harnessing the full potential of ZURZUVAE as
Sage Therapeutics, Inc. (NASDAQ:SAGE), today announced that it will host a live webcast on Tuesday, October 29, 2024 at 4:30 p.m. ET to review third quarter 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments ind
Achieved $7.4 million in ZURZUVAE™ (zuranolone) collaboration revenue during the second quarter of 2024 (50% of the net revenues recorded by Biogen), representing 19% growth from the first quarter More than 1,400 prescriptions shipped and delivered during the second quarter of 2024, nearly doubling from the first quarter Dalzanemdor (SAGE-718) topline data from the LIGHTWAVE (Alzheimer's Disease) and DIMENSION (Huntington's Disease) Studies expected in late 2024; primary endpoint for DIMENSION Study adjusted from HD-CAB composite to the Symbol Digit Modalities Test (SDMT) SAGE-324 did not meet the primary endpoint in participants with essential tremor (ET); Sage and Biogen terminated
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, July 31, 2024 at 4:30 p.m. ET to review second quarter 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health med
Achieved $6.2 million in ZURZUVAE™ (zuranolone) collaboration revenue during the first quarter of 2024, representing 50% of the net revenues reported by Biogen Encouraging initial demand for ZURZUVAE; More than 700 prescriptions shipped and delivered in the first quarter of 2024 Payor coverage now in place for a majority of commercially covered lives for ZURZUVAE in the treatment of women with postpartum depression (PPD) without step therapy or complex prior authorizations, including coverage from two national Pharmacy Benefit Managers (PBMs) Phase 2 PRECEDENT Study did not show statistically significant differences versus placebo on primary endpoint in patients with mild cognitive im
- In the Phase 2 PRECEDENT Study, dalzanemdor (SAGE-718) did not show statistically significant differences versus placebo on the primary endpoint in patients with mild cognitive impairment in Parkinson's disease - Dalzanemdor (SAGE-718) was generally well-tolerated and there were no new safety signals observed - Topline data readouts from the Phase 2 studies in Huntington's disease and Alzheimer's disease are expected later this year Sage Therapeutics, Inc. (NASDAQ:SAGE) announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) in Parkinson
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Thursday, April 25, 2024 at 8:00 a.m. ET to review first quarter 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medi
ZURZUVAE™ (zuranolone), the first-and-only oral treatment indicated for adults with postpartum depression (PPD), became commercially available mid-December; Sage achieved $0.8 million in collaboration revenue as of December 31, 2023, 50% of the net revenues Biogen reports for ZURZUVAE Encouraging early launch results for ZURZUVAE with approximately 120 prescriptions in December Catalyst rich 2024 with multiple topline data read-outs expected across dalzanemdor (SAGE-718) and SAGE-324 with potential for significant long-term value creation Strong financial foundation with year-end 2023 cash, cash equivalents and marketable securities of $753 million Sage Therapeutics, Inc. (NASDAQ:SA
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, February 14, 2024 at 8:00 a.m. ET to review fourth quarter and full year 2023 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changin
ZURZUVAE™ (zuranolone), first and only oral treatment approved for adults with postpartum depression (PPD), designated Schedule IV by the DEA; progressing towards planned commercial availability in December Announces expected wholesale acquisition cost of ZURZUVAE of $15,900 SAGE-718 granted FDA Orphan Drug Designation for the treatment of Huntington's Disease Sage product pipeline provides potential for significant value creation with topline data expected from multiple ongoing Phase 2 trials in 2024 Strong financial foundation with $876 million of cash, cash equivalents and marketable securities as of September 30, 2023 Sage Therapeutics, Inc. (NASDAQ:SAGE) today reported busine
JP Morgan analyst Anupam Rama downgrades Sage Therapeutics (NASDAQ:SAGE) from Overweight to Neutral and lowers the price target from $18 to $12.
Baird analyst Joel Beatty maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $15 to $13.
HC Wainwright & Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $25 price target.
Shares of General Dynamics Corporation (NYSE:GD) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter EPS results. Revenue for the quarter increased 18% year-over-year to $11.976 billion, beating the consensus of $11.438 billion. EPS of $3.26 (up 20.7% YoY) missed the consensus of $3.29, according to data from Benzinga Pro. General Dynamics shares declined 5.2% to $279.26 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers NuZee, Inc. (NASDAQ:NUZE) jumped 192% to $3.01. Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 142.4% to $3.0799 after falling over 22% on Tuesday. Selina Hospitality PLC
Sage Therapeutics Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) announced results Wednesday from the Phase 2 KINETIC 2 dose-range study of SAGE-324 (BIIB124) as a potential treatment for essential tremor (ET). The KINETIC 2 Study did not demonstrate a statistically significant dose-response relationship in change from baseline to Day 91 based on the primary endpoint, The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale (PS) Item 4 (upper limb) total score. TETRAS is used to quantify the severity of tremors and their impact on daily living activities. Also Read: Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson’s Dat
Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Hold.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Evercore ISI Group boosted the price target for Netflix, Inc. (NASDAQ:NFLX) from $700 to $710. Evercore ISI Group analyst Mark Mahaney maintained an Outperform rating. Netflix shares declined 0.7% to close at $643.04 on Thursday. See how other analysts view this stock. Keybanc increased the price target for Robinhood Markets, Inc. (NASDAQ:HOOD) from $23 to $25. Keybanc analyst Alex Markgraff maintained an Overweight rating. Robinhood shares fell 5.6% to close at $22.83 on Thursday. See how other an
Mizuho analyst Uy Ear maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $18 to $16.